Acurian shortens enrollment by 7 months for a crucial migraine Phase IIb study



It’s no surprise that doctors enthuse about the new CGRP class of migraine prevention drugs currently under development. More than 36 million Americans suffer from migraine attacks, and of these, about 4 million have chronic migraine.

Read More »